MYSM1 and inflammatory bowel disease: In the present study, we demonstrate that Mysm1‐deficient ASCs showed attenuated inhibition of T cell proliferation in vitro, while exacerbating inflammatory bowel diseases and inhibiting tumour growth in vivo.